UnknownPhase 2NCT02874326

Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber

Studying Hereditary hemorrhagic telangiectasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Radboud University Medical Center
Principal Investigator
Joost Drenth, MD PhD
Radboud University Medical Center
Intervention
Octreotide LAR(drug)
Enrollment
15 target
Eligibility
18 years · All sexes
Timeline
20162018

Study locations (2)

Collaborators

St. Antonius Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02874326 on ClinicalTrials.gov

Other trials for Hereditary hemorrhagic telangiectasia

Additional recruiting or active studies for the same condition.

See all trials for Hereditary hemorrhagic telangiectasia

← Back to all trials